Search Result

Results for "

terminal

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JNK (12) 5-HT Receptor (3) ADC Cytotoxin (2) ADC Linker (9) Adrenergic Receptor (3) Akt (1) Amino Acid Derivatives (3) Aminopeptidase (1) Amyloid-β (6) Androgen Receptor (11) Angiotensin Receptor (1) Angiotensin-converting Enzyme (ACE) (4) Antibiotic (6) Antifolate (1) Apelin Receptor (APJ) (1) Apolipoprotein (1) Apoptosis (37) Autophagy (6) Bacterial (16) Bcl-2 Family (2) Biochemical Assay Reagents (37) c-Myc (1) Calcium Channel (1) CaMK (1) Cannabinoid Receptor (1) Carboxypeptidase (2) Caspase (3) CCR (3) CD47 (2) CDK (6) CGRP Receptor (3) Chemerin Receptor (1) Cholecystokinin Receptor (1) CMV (1) Complement System (2) COX (1) CXCR (1) Dengue virus (1) Deubiquitinase (6) Dihydrofolate reductase (DHFR) (1) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (2) Dopamine Receptor (1) Drug Metabolite (2) E1/E2/E3 Enzyme (2) E3 Ligase Ligand-Linker Conjugates (8) EGFR (1) Endogenous Metabolite (30) Epigenetic Reader Domain (19) ERK (3) FAP (1) Farnesyl Transferase (4) Ferroptosis (13) FGFR (1) Flavivirus (1) Fluorescent Dye (25) Formyl Peptide Receptor (FPR) (2) Galectin (4) GCGR (5) GLP Receptor (2) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (1) Histone Methyltransferase (2) HIV (7) HSP (12) HSV (1) IFNAR (1) iGluR (16) IKK (1) Influenza Virus (3) Insulin Receptor (1) Integrin (1) Isotope-Labeled Compounds (8) Ligands for E3 Ligase (4) LIM Kinase (LIMK) (1) Liposome (10) mAChR (1) Macrophage migration inhibitory factor (MIF) (1) MAP3K (1) Melanocortin Receptor (2) Microtubule/Tubulin (1) MMP (1) Molecular Glues (1) Monoamine Transporter (2) mTOR (3) nAChR (2) NADPH Oxidase (1) Neurokinin Receptor (6) Neuropeptide Y Receptor (5) NF-κB (3) NO Synthase (2) Opioid Receptor (4) p38 MAPK (2) p97 (1) PACAP Receptor (2) Parasite (1) PDGFR (1) PI3K (3) Pim (1) PKA (1) PKC (2) Potassium Channel (2) PPAR (6) PROTAC Linkers (6) PROTACs (3) Protease Activated Receptor (PAR) (1) Proteasome (2) PTHR (1) Ribosomal S6 Kinase (RSK) (1) RIP kinase (1) Secretin Receptor (2) Ser/Thr Protease (2) Sialyltransferase (1) Sirtuin (1) Sodium Channel (1) Somatostatin Receptor (2) Src (6) Tau Protein (3) TGF-beta/Smad (1) Thyroid Hormone Receptor (1) Toll-like Receptor (TLR) (1) TRP Channel (3) TrxR (1) Tyrosinase (1) VEGFR (1) Wnt (1) α-synuclein (6) β-catenin (2)
By Research Areas:	Cancer (133) Cardiovascular Disease (26) Endocrinology (15) Infection (35) Inflammation/Immunology (49) Metabolic Disease (57) Neurological Disease (99)
Click Chemistry:	Labeling and Fluorescence Imaging (3) DBCO (5) PROTAC Synthesis (2) Azide (9) Tetrazine (3) Alkynes (15)
Oligonucleotides:	Nucleosides and their Analogs (1) Thickeners (1) Pegylated Lipids (3) CpG ODNs (1) Emulsifiers (1) Cationic Lipids (3) Phospholipids (3) Polymers (1) Cholesterol (1)

440

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

218

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: JNK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-E70016

Terminal deoxyribonucleotidyltransferase TdT	Others	Others Cancer
Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells .

HY-P4154

Bevonescein ALM-488	Fluorescent Dye	Neurological Disease
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .

HY-B1348

Dimethadione	Drug Metabolite	Neurological Disease
Dimethadione is the primary metabolite of trimethadione. Dimethadione causes depression of neuromuscular transmission. Dimethadione primarily decreases transmitter release from the nerve terminal .

HY-103323

*Fas C-Terminal* Tripeptide**	FAP	Others
Fas C-Terminal Tripeptide is a C-terminal tripeptide of Fas. Fas C-Terminal Tripeptide shows the inhibitory effect on Fas/FAP-1 binding .

HY-132273

Alkyne Phosphoramidite, 5'-terminal	Biochemical Assay Reagents	Others
Alkyne Phosphoramidite, 5'-terminal (Compound 2) can be used for synthesis of oligo-nucleotides.

HY-P5984

Thioether-cyclized helix B peptide, CHBP	mTOR	Others
Thioether-cyclized helix B peptide, CHBP can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .

HY-P5984A

Thioether-cyclized helix B peptide, CHBP TFA	mTOR	Others
Thioether-cyclized helix B peptide, CHBP (TFA) is the TFA form of Thioether-cyclized helix B peptide, CHBP (HY-P5984). Thioether-cyclized helix B peptide, CHBP (TFA) can improve metabolic stability and renoprotective effect through inducing autophagy via inhibition of mTORC1 and activation of mTORC2 .

HY-P10282

Synapsin I-(3-13)	CaMK	Neurological Disease
Synapsin I-(3-13), a substrate for CaMK1, is a glycoprotein. Synapsin I is a phosphoprotein that coats the cytoplasmic side of synaptic vesicles and regulates their trafficking within nerve terminals .

HY-159708

Ionizable lipid Az1	Liposome	Others
Ionizable lipid Az1is an ionizable lipid which can react with a variety of terminal alkynes under the CuAAC standard condition .

HY-125564

Acetyltrialanine	Aminopeptidase	Others
Acetyltrialanine is a peptide containing three amino acid residues in which the N-terminal amino acid is acetylated and used as a substrate for Nα-acetyl alanine aminopeptidase in order to study the activity and properties of the enzyme. Acetyltrialanine can be used in the study of protein degradation and N-terminal regulation .

HY-N5123

α-L-Rhamnose	Others	Others
α-L-Rhamnose is a terminal residue of steviol glycosides Dulcoside A and Dulcoside B. α-L-Rhamnose recognizing lectin site of human dermal fibroblasts functions as a signal transducer: modulation of Ca ²⁺ fluxes and gene expression .

HY-P1459

*Sphistin Synthetic Peptide(12-38,Fitc in N-Terminal-Fluorescently Labeled Peptide)*	Bacterial	Infection
Sphistin Synthetic Peptide (12-38, Fitc in N-Terminal-Fluorescently Labeled Peptide) is a truncated fragments of Sphistin Synthetic Peptide that shows potent antimicrobial activity.

HY-D1664

BDP 558/568 alkyne	Fluorescent Dye	Others
BDP 558/568 alkyne is a borondipyrromethene dye. BDP 558/568 alkyne possesses high quantum yield. BDP 558/568 alkyne is a terminal alkyne for copper-catalyzed Click chemistry. (λ_ex=558 nm, λ_em=568 nm) .

HY-102068

Clathrin-IN-1	HIV	Infection
Clathrin-IN-1 is a selective clathrin-mediated endocytosis (CME) inhibitor. Clathrin-IN-1 selectively inhibits amphiphysin association of clathrin terminal domain (TD) with an IC₅₀ value of 12 μM. Clathrin-IN-1 acutely interferes with receptor-mediated endocytosis, entry of HIV, and synaptic vesicle recycling .

HY-E70029

α-1,6-Fucosidase, lactobacillus casei	Others	Others
alpha-1,6-Fucosidase (LpAlfC(E274A)) (EC 3.2.1.51) cleaves branched non-reducing terminal fucose, linked α(1-6) to the core N-acetylglucosamine of N-linked oligosaccharides. alpha-1,6-Fucosidase (LpAlfC(E274A)) is useful for determining core fucosylation .

HY-150145

Cy5-UTP	Biochemical Assay Reagents	Others
Cy5-UTP is a substrate for terminal deoxynucleotidyl transferase (TdT). Cy5-UTP can be used to lable RNA probes through in vitro transcription (Excitation/Emission: 650/665 nm). Cy5-labeled mRNA emits orange fluorescence .

HY-109076

Tigilanol tiglate EBC-46	PKC	Cancer
Tigilanol tiglate (EBC-46) is a protein kinase C (PKC)/C1 domain activator. Tigilanol tiglate is a natural product with antitumor activity used for local administration against a variety of skin malignancies. Tigilanol tiglate is associated with mitochondrial/endoplasmic reticulum (ER) dysfunction, leading to activation of the unfolded protein response (UPRmt/ER) and subsequent induction of ATP depletion, organelles expansion, caspase activation, gasdermin E cleavage, and terminal necrosis. Tigilanol tiglate, as a small anti-tumor molecule with immunomodulatory effects, can be used in the study of head and neck squamous cell carcinoma and soft tissue sarcoma .

HY-18975

I-BRD9 5 Publications Verification	Epigenetic Reader Domain	Inflammation/Immunology Cancer
I-BRD9 is a selective cellular chemical probe of bromodomain-containing protein 9 (BRD9) with pIC₅₀ value of 7.3 μM. I-BRD9 has high selectivity for bromodomain and extra terminal domain (BET) family and highly homologous bromodomain-containing protein 7 (BRD7). I-BRD9 can be used to identify genes regulated by BRD9 in Kasumi-1 cells involved in oncology and immune response pathways .

HY-D1517

FM 2-10	Fluorescent Dye	Others
FM 2-10 is a fluorescent dye. FM 2-10 is a less hydrophobic version of FM 1-43 (HY-D1434). FM 2-10 can be used for identifying actively firing neurons and investigating the mechanisms of activity-dependent vesicle cycling .

HY-P1170

N-terminally acetylated Leu-enkephalin Ac-L-Tyr-Gly-Gly-L-Phe-D-Leu-COOH	Opioid Receptor	Neurological Disease
N-terminally acetylated Leu-enkephalin is the N-terminally acetylated form of Leu-enkephalin. Leu-enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

HY-P10527

CSK substrate	Src	Others
CSK substrate is a specific substrate for *C-terminal* Src kinase (CSK*), which binds CSK and downregulates the Src family members. CSK substrate preferentially phosphorylates certain amino acid residues that are distinct from the conserved Src C-terminal* sequence .

HY-E70055

α-2,6-Sialyltransferase, pasteurella multocida (P-1059)	Sialyltransferase	Others
alpha-2,6-Sialyltransferase (Pd26ST) (EC 2.4.99.1) is capable of sialylating both terminal and internal galactose and N-acetylgalactosamine, which producing terminal α2,6-sialosides .

HY-P1228

HAEGTFT	GCGR	Metabolic Disease
HAEGTFT is the first N-terminal 1-7 residues of GLP-1 peptide.

HY-P1224

HAEGTFTSDVS	GCGR	Metabolic Disease
HAEGTFTSDVS is the first N-terminal 1-11 residues of GLP-1 peptide.

HY-145125

SJ995973	PROTACs	Others
SJ995973 (PROTAC) is a uniquely potent degrader of *bromodomain and extra-terminal* (BET)** proteins.

HY-14608S2

L-Glutamic acid-15N	Endogenous Metabolite iGluR Ferroptosis Apoptosis	Neurological Disease
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[1].

HY-P1499

Somatostatin-28 (1-14)	Somatostatin Receptor	Neurological Disease
Somatostatin-28 (1-14) is an N-terminal fragment of the neuropeptide somatostatin-28.

HY-52101A

FMK 3 Publications Verification	Ribosomal S6 Kinase (RSK)	Cancer
FMK is a an irreversible RSK2 kinase inhibitor, that covalently modifies the C-terminal kinase domain of RSK.

HY-P1062

Lauryl-LF 11	Bacterial Antibiotic	Infection
Lauryl-LF 11, N-terminally acylated analogue of LF11, is a peptide with antibacterial activity .

HY-103076

EZ-482 1 Publications Verification	Apolipoprotein	Neurological Disease
EZ-482, a novel ligand of apolipoprotein (apoE), binds to sites on apoE in the C-terminal domain with K_ds of 5-10 μM for apoE3 and apoE4. EZ-482 binds to apoE4 by a unique N-terminal allosteric effect. EZ482 has the potential for Alzheimer’s diseas .

HY-14608S10

L-Glutamic acid-13C2	Apoptosis iGluR Ferroptosis Endogenous Metabolite	Neurological Disease
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid[1]. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[2].

HY-P1062A

Lauryl-LF 11 TFA	Bacterial Antibiotic	Infection
Lauryl-LF 11 TFA, N-terminally acylated analogue of LF11, is a peptide with antibacterial activity .

HY-P2549

Biotin-β-Amyloid (1-40)	Fluorescent Dye	Neurological Disease
Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-?-(1-40) peptide.

HY-139623

A4B17	Androgen Receptor	Cancer
A4B17 is an androgen receptor N-terminal inhibitor for researching androgen-responsive prostate cancer.

HY-151665

Alkyne-PEG2-iodide	ADC Linker	Others
Alkyne-PEG2-iodide is a click chemistry reagent with terminal alkyne and alkyl iodide groups.

HY-N1455

Falcarinol Panaxynol; Carotatoxin	HSP Apoptosis	Cancer
Falcarinol (Panaxynol) is a natural, orally active Hsp90 inhibitor targeting both the N-terminal and C-terminal of Hsp90 with limited toxicities. Falcarinol (Panaxynol) induces apoptosis . Falcarinol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P2746

Carboxypeptidase B, Porcine pancreas EC 3.4.2.2	Endogenous Metabolite	Metabolic Disease
Carboxypeptidase B, Porcine pancreas (EC 3.4.2.2) is a peptide exonuclease that can specifically degrade peptide chains. Carboxypeptidase B is progressively degraded from the C-terminal to release free amino acids. Carboxypeptidase B hydrolyzes only peptide bonds with basic amino acids (such as arginine and lysine) as C-terminal residues .

HY-140015A

(S,E)-TCO2-PEG3-acid	PROTAC Linkers	Cancer
(S)-TCO-PEG3-acid is a click chemistry PEG linker with a terminal carboxylic acid(COOH) group. The terminal carboxylic acid is reactive with primary amine groups to form a stable amide bond. (S)-TCO-PEG3-acid is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.

HY-E70201

Carboxypeptidase B (MS grade) EC 3.4.2.2 (MS grade)	Endogenous Metabolite	Others
Carboxypeptidase B (MS grade) is a peptide exonuclease that can specifically degrade peptide chains. Carboxypeptidase B (MS grade) is progressively degraded from the C-terminal to release free amino acids. Carboxypeptidase B (MS grade) hydrolyzes only peptide bonds with basic amino acids (such as arginine and lysine) as C-terminal residues .

HY-13506

M344 2 Publications Verification D 237; MS 344	HDAC	Cancer
M344 (D 237) is an inhibitor of histone deacetylase (IC₅₀=100 nM) and an inducer of terminal cell fifferentiation.

HY-P2643

Angiotensin I/II (4-8)	Endogenous Metabolite	Cardiovascular Disease
Angiotensin I/II (4-8), a major metabolite of Angiotensin II, is a C-terminal 4-8 pentapeptide .

HY-114669

Polyoxin C	Others	Others
Polyoxin C, the hybrid compound of nucleosides and R-amino acids, is important as the C-terminal amino acid component of Nikkomycin .

HY-156862

(+)-Chloroquine	Others	Others
(+)-Chloroquine is a aminoquinoline drug impairs in vitro the terminal glycosylation of angiotensin-converting enzyme 2 (ACE-2) .

HY-P1492

Substance P (7-11)	Neurokinin Receptor	Neurological Disease Endocrinology
Substance P (7-11) is a C-terminal fragment of Substance P which can cause an increase in the intracellular calcium concentration.

HY-P3208

Endoproteinase Lys-C	Others	Others
Endoproteinase Lys-C is a protease that cleaves proteins on the C-terminal side of lysine residues and is commonly used for protein sequencing .

HY-P5748

Bac5(1-25)	ADC Cytotoxin	Others
Bac5(1-25) is an N-terminal fragment of the bovine proline-rich antimicrobial peptide Bac5 .

HY-E70196

Endoproteinase Asp-N Asp-N	MMP	Others
Endoproteinase Asp-N (Asp-N) is a metalloprotease that can specifically cleave the N-terminal side of aspartyl and cysteic acid residues .

HY-151894

I-BET432	Epigenetic Reader Domain	Cancer
I-BET432 is a BET inhibitor. I-BET432 inhibits BRD4 N-terminal bromodomain (BD1) and the C-terminal bromodomain (BD2) with pIC₅₀ values of 7.5 and 7.2, respectively. I-BET432 can be used as an oral candidate quality molecule for the research of multiple oncology and inflammatory diseases .

HY-P99777

Ontorpacept TTI-621	CD47	Cancer
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .

HY-P0266

N-Acetyl-Ser-Asp-Lys-Pro Ac-SDKP	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease Inflammation/Immunology
N-Acetyl-Ser-Asp-Lys-Pro, an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N-terminal site of ACE.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-E70016

Terminal deoxyribonucleotidyltransferase TdT	Classification of Application Fields Disease Research Fields Cancer	Others
Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells .

HY-N1455

Falcarinol Panaxynol; Carotatoxin	Structural Classification Natural Products Classification of Application Fields Ambrosia psilostachya DC. Source classification Umbelliferae Plants Disease Research Fields Cancer	HSP Apoptosis
Falcarinol (Panaxynol) is a natural, orally active Hsp90 inhibitor targeting both the N-terminal and C-terminal of Hsp90 with limited toxicities. Falcarinol (Panaxynol) induces apoptosis . Falcarinol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P99777

Ontorpacept TTI-621	Classification of Application Fields Disease Research Fields Cancer	CD47
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .

HY-121687

HIPP α-(Hydroxyimino)benzenepropanoic acid	Structural Classification Natural Products Marine natural products Source classification	Others
HIPP (α-(Hydroxyimino)benzenepropanoic acid) is an inhibitor for human C-terminal binding protein (CtBP), with IC₅₀ of 745 nM and a K_d of 1.3 μM .

HY-N8920

Syringetin	Flavonols Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Others
Syringetin, a flavonoid derivative, is associated with increased BMP-2 production. Syringetin stimulates osteoblast differentiation at various stages, from maturation to terminally differentiated osteoblasts .

HY-W040047

Pregnanediol 3-glucuronide	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Endocrinology Steroids	Endogenous Metabolite
Pregnanediol 3-glucuronide is the major terminal metabolite of progesterone, playing an important role in physiological processes, such as the female menstrual cycle, pregnancy (supports gestation), embryogenesis and maternal immune response of humans and other species .

HY-125564

Acetyltrialanine	Structural Classification Natural Products Microorganisms Source classification	Aminopeptidase
Acetyltrialanine is a peptide containing three amino acid residues in which the N-terminal amino acid is acetylated and used as a substrate for Nα-acetyl alanine aminopeptidase in order to study the activity and properties of the enzyme. Acetyltrialanine can be used in the study of protein degradation and N-terminal regulation .

HY-N5123

α-L-Rhamnose	Microorganisms Classification of Application Fields Source classification Other Diseases Disease Research Fields Saccharides Monosaccharides	Others
α-L-Rhamnose is a terminal residue of steviol glycosides Dulcoside A and Dulcoside B. α-L-Rhamnose recognizing lectin site of human dermal fibroblasts functions as a signal transducer: modulation of Ca ²⁺ fluxes and gene expression .

HY-P0266A

N-Acetyl-Ser-Asp-Lys-Pro TFA Ac-SDKP TFA	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Animals Source classification Disease Research Fields	Angiotensin-converting Enzyme (ACE)
N-Acetyl-Ser-Asp-Lys-Pro (TFA), an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N-terminal site of ACE.

HY-108826

Iduronate sulfatase Iduronate sulfate sulfatase	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Iduronate sulfatase (Iduronate sulfate sulfatase) is an exo-sulfatase that hydrolyzes the C2-sulfate ester bond from nonreducing terminal α-L-iduronic acid residues in HS .

HY-132178

Cytochrome P450	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Cytochrome P450 is a family of monooxygenase enzymes that catalyzes the conversion of fatty acids to terminal alkenes using hydrogen peroxide as a cosubstrate. Cytochrome P450 as membrane-bound hemoproteins, plays important roles in the detoxification of drugs, cellular metabolism, and homeostasis .

HY-P1841

Glucagon-Like Peptide (GLP) II, human	Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Apoptosis
Glucagon-Like Peptide (GLP) II, human is a 33-amino acid peptide derived from the C-terminal of proglucagon and mainly produced by the intestinal L cells. Glucagon-Like Peptide (GLP) II, human stimulates intestinal mucosal growth and decreases apoptosis of enterocytes .

HY-113273B

Diadenosine pentaphosphate pentaammonium	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Diadenosine pentaphosphate pentaammonium is an endogenous vasoactive purine dinucleotide which has been isolated from thrombocytes. Diadenosine polyphosphates (ApnA, n=2–7) have been identified as constituents of secretory vesicles such as in platelets, chromaffin cells, Torpedo synaptic terminals and brain synaptosomes .

HY-113273C

Diadenosine pentaphosphate pentalithium	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Diadenosine pentaphosphate pentalithium is an endogenous vasoactive purine dinucleotide which has been isolated from thrombocytes. Diadenosine polyphosphates (ApnA, n=2–7) have been identified as constituents of secretory vesicles such as in platelets, chromaffin cells, Torpedo synaptic terminals and brain synaptosomes .

HY-113273A

Diadenosine pentaphosphate pentasodium	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Diadenosine pentaphosphate pentasodium is an endogenous vasoactive purine dinucleotide which has been isolated from thrombocytes. Diadenosine polyphosphates (ApnA, n=2–7) have been identified as constituents of secretory vesicles such as in platelets, chromaffin cells, Torpedo synaptic terminals and brain synaptosomes .

HY-P9914

Eculizumab Anti-Human C5, Humanized Antibody	Classification of Application Fields Disease Research Fields Cancer	Complement System
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .

HY-114365

UDP-GalNAc disodium UDP-N-acetyl-D-galactosamine disodium	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
UDP-GalNAc (UDP-N-acetyl-D-galactosamine) disodium is a sugar nucleotide and a substrate of EpsC115. EpsC115 is an exopolymeric substances (EPS) N-terminal deletion mutant with the residue 1-115 deletion. UDP-GalNAc UDP-GalNAc is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GalNAc from the nucleotide sugar to a saccharide or peptide acceptor .

HY-128852

N-Acetyl-D-galactosamine, 98%	Structural Classification Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields Saccharides Monosaccharides	Galectin Endogenous Metabolite
N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. N-Acetyl-D-galactosamine (GalNAc) interact with Soya bean agglutinin (SBA), hence decreasing the effects of SBA on cellular membrane permeability and tight junction protein expression in piglets . N-Acetyl-D-galactosamine (GalNAc) inhibits the hemagglutinating activity by the lectin .

HY-119906

Conglobatin FW-04-806	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	HSP Apoptosis
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active Hsp90 inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-122815

Fusicoccin Fusicoccin A	Microorganisms Classification of Application Fields Terpenoids Source classification Diterpenoids Disease Research Fields Cancer	Apoptosis
Fusicoccin (Fusicoccin A), a fungal pytotoxin, is a stabilizer of specific 14-3-3 protein-protein interactions. Fusicoccin sabilizes H ⁺-ATPase/14-3-3 cmplex in pants, maintaining the enzyme in activated state. Fusicoccin also stabilizes 14-3-3 protein interactions with binding partners containing a C-terminal 14-3-3 recognition motif (a mode 3 motif), such as ERα, GPIbα, TASK3, CTFR, and p53. Fusicoccin induces apoptosis in cancer cells and has anticancer activity .

HY-137566

Cucumarioside H	Triterpenes Structural Classification Animals Terpenoids Source classification	Others
Cucumarioside H is a novel triterpene glycoside isolated from the Far Eastern sea cucumber Eupentacta fraudatrix, including H2, H3 and H4. These glycosides have a branched pentasyl structure with a rare 3-O-methyl-D-xylose as the terminal monosaccharide. H2 contains 23,24,25,26,27-pentanolone sterols and has an 18(16)-lactone, which is not common in sea cucumbers. The glycoside portion of H3 contains an extremely rare ethoxyl radical at the 25 position, which may be an artifact formed during the long ethanol extraction process. Studies have shown that H1-3 are cytotoxic to mouse spleen lymphocytes, hemolytic to mouse erythrocytes, and cytotoxic to Ehrlich carcinoma cells. The presence of a 25-hydroxyl group in the glycoside portion significantly reduces these activities.

Cat. No.	Product Name	Chemical Structure

HY-14608S2

L-Glutamic acid-15N
L-Glutamic acid- ¹⁵N is the ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[1].

HY-W007798S1

Fmoc-Cys(Trt)-OH-d2
Fmoc-Cys(Trt)-OH-d₂ is the deuterium labeled Fmoc-Cys(Trt)-OH. Fmoc-Cys(Trt)-OH is an N-terminal protected cysteine derivative[1].

HY-14608S7

L-Glutamic acid-d5
L-Glutamic acid-d₅ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S8

L-Glutamic acid-d3
L-Glutamic acid-d₃ is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S5

L-Glutamic acid-13C5
L-Glutamic acid- ¹³C₅ is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S1

L-Glutamic acid-1-13C
L-Glutamic acid-1- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S10

L-Glutamic acid-13C2
L-Glutamic acid- ¹³C₂ is the ¹³C labeled L-Glutamic acid[1]. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals[2].

HY-150516S

BET-IN-12
BET-IN-12 is an orally avtive inhibitor of bromodomain and extra-terminal (BET) with an IC50 of 0.9 nM for BRD4[1].

HY-14608S

L-Glutamic acid-13C
L-Glutamic acid- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S6

L-Glutamic acid-5-13C
L-Glutamic acid-5- ¹³C is the ¹³C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S3

L-Glutamic acid-13C5,15N
L-Glutamic acid- ¹³C₅, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-14608S9

L-Glutamic acid-15N,d5
L-Glutamic acid- ¹⁵N,d₅ is the deuterium and ¹⁵N-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-P5201S

VTSEGAGLQLQK-13C6,15N2
VTSEGAGLQLQK- ¹³C₆, ¹⁵N₂ is the ¹³C and ¹⁵N labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect .

HY-P5201S1

VTSEGAGLQLQK-13C6,15N2 TFA
VTSEGAGLQLQK- ¹³C₆, ¹⁵N₂ (TFA) is the ¹³C- and ¹⁵N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .

HY-14608S4

L-Glutamic acid-13C5,15N,d5
L-Glutamic acid- ¹³C₅, ¹⁵N,d₅ is the deuterium, ¹³C-, and 15-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.

HY-117727S

Leriglitazone-d4

Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks